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Edited by Laszola NagyAbstract The expression, regulation and functional signiﬁcance
of multiple peroxisome proliferator-activated receptor c tran-
script variants in bone were studied. PPARG transcripts giving
rise to PPARg-1 protein were expressed in human osteoblasts,
whereas PPARG-2 transcript and protein remained virtually ab-
sent. PPARG expression underwent homologous regulation, was
upregulated during diﬀerentiation and directly induced by the
osteogenic hormone dexamethasone, suggesting a role for
PPARg-1 in osteogenesis. Diﬀerences between the stabilities of
PPARG-1, -3 and -4 were observed. We hypothesize that cell-
speciﬁc expression patterns of multiple PPARG transcript vari-
ants encoding for the same protein but diﬀering in mRNA stabil-
ities enable a ﬁne-tuning of PPARG action, which eventually
supports a well-adjusted signal transduction between the cell
and its environment.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Peroxisome proliferator-activated receptor c (PPARG) is a
nuclear transcription factor that plays roles in the control of
proliferation, diﬀerentiation and survival of various cell types
(reviewed in [1]). The single PPARG gene undergoes alterna-
tive splicing and promoter usage giving rise to two proteins:
PPARg-1 and PPARg-2 (Fig. 1; [2]). PPARg-2 contains an
additional N-terminal exon that results in a higher trans-
activation capacity compared to PPARg-1 [3]. Besides this
functional diﬀerence at protein level, there is an additional
complexity at its transcript level. Interestingly, PPARg-1 pro-
tein can be translated from the three PPARG transcripts
PPARG-1, -3 and -4 that only diﬀer in their 5 0-untranslated re-
gion [4]. The existence of multiple transcript variants encodingbbreviations: PPARG, peroxisome proliferator-activated receptor c
EX, dexamethasone; ROSI, rosiglitazone; VSMC, vascular smooth
uscle cells; MSC, mesenchymal stem cells
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.ieties. Pufor the same protein has been reported for other genes as well
[5], but its functional signiﬁcance has not been revealed yet.
PPARg-1 protein is expressed in many cell types, whereas
the expression of PPARg-2 is mainly limited to adipocytes
[6–8]. Also, it has been reported that PPARg-1 is expressed
in a murine pre-osteoblastic cell line [9,10].
In this study, we investigated the diﬀerential expression of
the four PPARG transcript variants in human pre-osteoblast
and osteoblast-like cells and in human mesenchymal stem cells
(MSCs) that were driven to diﬀerentiate towards the osteoblas-
tic lineage. Furthermore the eﬀect of the osteoblast diﬀerentia-
tion-inducing hormone dexamethasone (DEX) and the
PPARG agonist rosiglitazone (ROSI) on PPARG expression
in human osteoblasts were investigated.2. Materials and methods
2.1. Cell culture
SV-HFO cells [11], normal human osteoblasts (NHOST; Cambrex
Bio Science CC-2538, East Rutherford, NJ, USA), human vascular
smooth muscle cells (VSMC; Cambrex Bio Science, CC-2583) and hu-
man MSCs (Cambrex Bio Science) were cultured as described previ-
ously [12].
2.2. Quantiﬁcation of mRNA expression
RNAisolationandcDNAsynthesis havebeen carriedout as described
recently [13] except that the total amount of RNA was quantiﬁed spec-
trophotometrically using NanoDrop technology (Bancroft Building
Wilmington, DE, USA) according to the manufacturers instructions.
Quantitative real time-PCR (QPCR) was either based on FAM/TAM-
RA or SYBR Green detection. FAM/TAMRA-based QPCR was per-
formed as described previously [13] with the exception that reaction
mixes contained 8 instead of 20 ng cDNA. SYBRGreen-based QPCR
was carried out using an ABI 7700 sequence detection system (Applied
Biosystems, Foster City, CA). Reactions were performed in 25 ll
volumes using qPCR core kit for SYBR Green I (Eurogentec, Seraing,
Belgium). Reaction mixes contained 8 ng cDNA, 3.5 mM MgCl2,
200 lMdNTPs and 0.025 U/ll HotGoldStar enzyme. Primer and probe
sequences as well as their concentrations are listed in Table 1.
2.3. Short-term incubation studies with DEX, RU-486 or ROSI
Medium was supplemented with 10 lM ROSI (Cayman Europe;
Tallin, Estonia), 100 nM DEX in the absence or presence of 2 lM of
the glucocorticoid receptor antagonist RU-486 (Sigma) at speciﬁc time
points (3, 6, 12, 24 and 48 h) before harvest at day 12 of culture. For
short-term ROSI incubations, SV-HFO cells were grown in the contin-
uous presence of 100 nM DEX. For short-term DEX and RU-486
incubations, SV-HFO cells were grown in the medium as described
above with the exception that DEX was not added continuously. Then
RNA was isolated and QPCR was performed as described above.blished by Elsevier B.V. All rights reserved.
Fig. 1. Exon–intron structures of multiple PPARG transcripts. Exons are depicted as grey squares and separated from each other by intronic
sequences (black lines). The positions and sizes do not match real scale. Sequences underlying this ﬁgure were received from the NCBI database
(received at 12, 11, 2007 from the NCBI on-line database/Entrez Gene, http://www.ncbi.nlm.nih.gov).
Table 1
Primer and probe concentrations and sequences
GAPDH
300 nM Forward 5 0-ATGGGGAAGGTGAAGGTCG-30
300 nM Reverse 5 0-TAAAAGCAGCCCTGGTGACC-30
150 nM Probe 50-FAM-CGCCCAATACGACCAAATCCGTTGACTAMRA-30
PPARG 1 (NM_138712)
50 nM Forward 5 0-GTGGCCGCAGATTTGAAAGAAG-30
50 nM Reverse 5 0-TGTCAACCATGGTCATTTCG-30
PPARG 2 (NM_015869)
50 nM Forward 5 0-CAAACCCCTATTCCATGCTGTT-30
50 nM Reverse 5 0-AATGGCATCTCTGTGTCAACC-3 0
PPARG 3 (NM_138711)
50 nM Forward 5 0-AGAAGCCTGCATTTCTGCAT-30
50 nM Reverse 5 0-TGGCCTTGTTGTATATTTGTGGTT-30
PPARG 4 (NM_005037)
50 nM Forward 50-GTGGCCGCAGAAATGACCATG-30
50 nM Reverse 5 0-GAGAGATCCACGGAGCTGAT-30
ANGPTL4
50 nM Forward 5 0-GACAAGAACTGCGCCAAGAG-30
50 nM Reverse 5 0-AGTACTGGCCGTTGAGGTTG-30
FABP4
50 nM Forward 5 0-TACTGGGCCAGGAATTTGAC-30
50 nM Reverse 5 0-GGACACCCCCATCTAAGGTT-30
ADFP
50 nM Forward 5 0-CAGAAGCTAGAGCCGCAAAT-30
50 nM Reverse 5 0-AGCCCCTTACAGGCATAGGT-30
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Medium was supplemented with 100 nM DEX at 3 h before harvest
at day 12 of SV-HFO culture. Before DEX incubation, cells were pre-
treated with 10 lg/ml of the protein biosynthesis inhibitor cyclohexi-
mide (Sigma) for 15 min. Then RNA was isolated and QPCR was per-
formed as described above.
2.5. Actinomycin D treatment
SV-HFO cells were cultured as described above until day 7 of cul-
ture. At 6, 12, 24 and 48 h before harvesting, actinomycin D (2 lg/
ml; Sigma) was added to the cultures. Then RNA was isolated and
QPCR was performed as described above.
2.6. Western blotting
Cells were solubilized in lysis buﬀer (M-PER Mammalian extraction
kit; Pierce Rockford, IL, USA). Total protein concentrations were
quantiﬁed using BCA protein assay kit (Pierce). Fifty micrograms of
total protein extract were loaded on an SDS–polyacrylamide gel con-
sisting of a 5% (w/v) stacking and a 10% (w/v) running gel. After elec-
trophoretic separation, samples were transferred to Nitrocellulose
blotting membrane (Hybond; Amersham Pharmacia, UK). Unspeciﬁcbinding sites were blocked using 4% skim milk in TBS without Tween
for over-night at 4 C. Then, the membrane was incubated in primary
antibody solution (primary antibody diluted in TBS with 0.1% TBS-
Tween and 1% skim milk) for 1 h at room temperature on a roller
bank. The dilution for rabbit polyclonal antibody against PPARG
was 1:1000 (Cat. 600-401-419; Rockland Gilbertsville, PA, USA).
Mouse monoclonal antibody against GAPDH (Cat. MAB374; Milli-
pore) was used as an internal calibrator in a dilution of 1:20000
and incubated for 30 min at room temperature. The membrane was
washed four times in 0.1% (v/v) TBS-Tween and incubated in a diluted
secondary antibody solution (secondary antibody diluted in TBS with
0.1% TBS-Tween and 1% skim milk) for 1 h at room temperature. The
secondary antibodies, anti-rabbit IgG conjugated with IRDye 800CW
(Cat. 17122; Rockland) and anti-mouse IgG conjugated with Alexa
Fluor 680 (Cat. A21057; Invitrogen) were used in a 1:10000 dilution
for 1 h at room temperature to detect the respective primary antibody.
After washing the membrane four times in 0.1% (v/v) TBS-Tween and
having removed residual Tween by washing in TBS only, ﬂuorescence
was detected and analyzed using LI-COR Infrared Imaging System
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Data presented are the results of at least two independent experi-
ments performed in at least triplicate. Values are the means ± S.E.M.
Signiﬁcance was calculated using the Students t-test.3. Results
3.1. Expression of PPARG and its primary target genes
The cell models used all proceed through a diﬀerentiation
process resulting in the production of a mineralized extra-
cellular matrix in a 2–3-week period [12]. PPARG expression
was demonstrated during the diﬀerentiation of the two
human pre-osteoblast cell lines SV-HFO (Fig. 2A), NHOST
(Fig. 2B) and MSCs that were diﬀerentiated towards the osteo-
blast lineage (Fig. 2C). In addition, PPARG expression was
demonstrated in mineralizing VSMC that are an experimental
model of arthrosclerosis (Fig. 2D). The expression levels of theig. 2. Expression levels of multiple PPARG transcripts encoding for PPAR
steoblast-like cells. Q-PCR of PPARG transcripts 1–4 in the human pre-oste
erived mesenchymal stem cells diﬀerentiated towards osteoblasts MSC (C), hu
edium lacking the osteogenic diﬀerentiation factor DEX (E). Expression leve
f at least three biological replicates ± S.E. Western blotting of PPARg-1 (up
and) was used as loading control. 3, 14: SV-HFO culture days 3 and 14, resfour PPARG transcript variants PPARG-1,-2, -3 and -4 at var-
ious time points during culture were quantiﬁed by QPCR.
Expression levels of PPARG-1, -3 and -4 were signiﬁcantly in-
creased during diﬀerentiation and mineralization of all the four
cell models. PPARG-2 expression, however, was virtually ab-
sent in SV-HFO, NHOST and VSMC and signiﬁcantly lower
compared to PPARG-1 in MSCs (Fig. 2A–D). Interestingly,
PPARG expression levels were virtually absent and did not
increase in the non-mineralizing condition, i.e. when cells were
not stimulated with DEX to diﬀerentiate towards a mineral-
ized matrix-producing osteoblast (Fig. 2E). Finally, the
presence of PPARg-1 protein and its increase during diﬀeren-
tiation (from day 3 to 14 of SV-HFO culture) was conﬁrmed
by western blotting (Fig. 2F). In addition, expression levels
of the conﬁrmed primary PPARG targets ANGPTL4, ADFP
and FABP4 [14,15] increased during diﬀerentiation of
SV-HFO (Fig. 3).g-1 protein increase during diﬀerentiation of human osteoblasts and
oblast cell lines SV-HFO (A) and NHOST (B), human bone marrow-
man vascular smooth muscle cells VSMC (D) and SV-HFO grown on
ls are relative to the housekeeping gene GAPDH. Values are the mean
per band) in SV-HFO at day 3 and 14 of culture (F). GAPDH (lower
pectively; L: protein standard.
Fig. 3. Expression levels of primary PPARG target genes increase during osteoblast diﬀerentiation. Q-PCR of ANGPTL4 (A), ADFP (B) and
FABP4 (C) in the human osteoblast cell line SV-HFO at multiple time points during diﬀerentiation. Expression levels are relative to the housekeeping
gene GAPDH. Values are the mean of at least three biological replicates ± S.E.
Fig. 4. Glucocorticoid receptor-regulated expression of PPARG. SV-HFO cells were short-term incubated with the cortisol analog DEX and/or the
glucocorticoid receptor antagonist RU-486 at day 12 of culture. Transcript levels were measured using QPCR. Values are relative to the
housekeeping gene GAPDH and the mean of at least three biological replicates ± S.E. Asterisks (*) denote values that were determined to be
signiﬁcantly (P 6 0.05) diﬀerent from those of control.
















Fig. 7. Diﬀerential stabilities of the three PPARG transcripts
PPARG-1, -3 and -4 encoding for PPARg-1 protein. The polymerase
II inhibitor actinomycin D was added at 6, 12, 24 and 48 h before
1622 C. Bruedigam et al. / FEBS Letters 582 (2008) 1618–16243.2. Direct regulation of PPARG expression by DEX
Short-term treatment with the synthetic cortisol analog
DEX during early diﬀerentiation of SV-HFO (day 12) showed
already after 3 h signiﬁcant increases in expression levels of
PPARG transcripts-1, -3 and -4 (Fig. 4). The expression further
increased when DEX was added to the medium for 6, 24 and
48 h before harvest. Induction of PPARG-1, -3 and -4 expres-
sion levels was completely blocked by the glucocorticoid recep-
tor antagonist RU-486 (Fig. 4). In addition, blocking de novo
protein biosynthesis using cycloheximide did not eﬀect the
stimulatory action of DEX on PPARG-1, -3 and -4 expression
(Fig. 5).
3.3. Homologous regulation of PPARG
ROSI is a well-studied PPARG agonist and stimulates
PPARG signalling in several target tissues (reviewed in [16]).
We found that, after short-term treatment with ROSI,
PPARG-1, -3 and -4 transcript levels were signiﬁcantly increased
(Fig. 6). PPARG-4 transcript was already signiﬁcantly inducedig. 5. De novo protein biosynthesis is not required for induction of
PARG expression by dexamethasone. SV-HFO cells were short-term
ncubated with the DEX and/or the protein synthesis inhibitor
ycloheximide. Transcript levels were measured using QPCR. Values
re relative to the housekeeping gene GAPDH and the mean of at least
hree biological replicates ± S.E. Asterisks (*) denote values that were
etermined to be signiﬁcantly (P 6 0.05) diﬀerent from those of
ontrol.
ig. 6. Homologous regulation of PPARG. Rosiglitazone was added
o the SV-HFO cultures at distinct time points before harvest at day 7.
ranscript levels were measured using QPCR. Values are relative to
he housekeeping gene GAPDH and the mean of at least three
iological replicates ± S.E. Asterisks (*) denote values that were
etermined to be signiﬁcantly (P 6 0.05) diﬀerent from those of
ontrol.
harvest at day 7. Data have been obtained by QPCR. Values are
expression levels relative to GAPDH and normalized to control.after 3 h of treatment compared to control, and increases in
PPARG-3 and -1 expression levels reached signiﬁcance after 6
or 12 h, respectively. However, PPARG-2 expression was not in-
duced upon ROSI-treatment (data not shown).
3.4. Diﬀerential dynamics for expression of PPARG splice
variants
By analyzing the stabilities of the PPARG transcripts using
the RNA polymerase II blocker actinomycin D in a time-
course experiment, we observed that the stabilities surprisingly
diﬀered between the PPARG transcripts 3 and 1/4 (Fig. 7). The
half-life of the PPARG transcripts-1 and -4 was about 24 h.
The PPARG-3 transcript had about a 6-fold shorter half-life
of 4 h.4. Discussion
The aim of the current study was to assess expression and
regulation of PPARG in human osteoblasts. They are bone-
forming cells and have the unique function to produce and
mineralize an extracellular protein matrix. Osteoblasts under-
go several developmental phases through their lifetime: early
commitment to organic-matrix production, mineralization
and apoptosis or terminal diﬀerentiation into an osteocyte.
The complex developmental process is orchestrated by the
timely activation of speciﬁc transcription factors that regulate
the expression of their target genes and thus deﬁne the osteo-
blast phenotype (reviewed in [17]). The current study demon-
strates increasing expression levels of three PPARG
transcripts-1, -3 and -4 giving rise to PPARg-1 protein but
not PPARG-2 encoding for PPARg-2 protein during diﬀeren-
tiation of the two human pre-osteoblast cell lines SV-HFO and
NHOST. We furthermore found that PPARG expression
levels increased duringMSC diﬀerentiation towards the osteo-
blastic lineage. And, ﬁnally the observations in the osteoblasts
were conﬁrmed in a VSMC-based model for vascular calciﬁca-
tion that mimics matrix formation and mineralization by the
osteoblasts. In the absence of diﬀerentiation towards matrix
C. Bruedigam et al. / FEBS Letters 582 (2008) 1618–1624 1623producing and mineralizing cells, PPARG transcript levels are
virtually absent and do not increase during culture time. In
addition, transcript levels of three conﬁrmed primary PPARG
target genes ANGPTL4, FABP4 and ADFP increase during
osteoblast diﬀerentiation, which correlates with the changes
in expression levels of PPARG transcripts-1, -3 and -4. To-
gether these data show a clear coupling between PPARg-1
expression and extracellular matrix synthesis and mineraliza-
tion indicating a role for PPARg-1 signalling in these pro-
cesses.
Presence of DEX is crucial for all cell models examined to
develop into a mineralizing condition [18]. Our short-term
DEX incubation studies demonstrated that PPARG expres-
sion is directly stimulated by DEX. Addition of the glucocor-
ticoid receptor antagonist RU-486 blocked the DEX eﬀect. In
silico searches for putative glucocorticoid receptor response
elements (GRE) in the promoter region of the PPARG gene re-
vealed several hits close to the transcription start sites (Tatjana
Degenhardt, personal communication). In addition, blocking
de novo protein biosynthesis using cycloheximide did not
change the stimulatory action of DEX on PPARG expression.
These data demonstrate that PPARG is a direct glucocorticoid
receptor target gene, however, the analysis of functional gluco-
corticoid receptor response elements in the PPARG gene will
be necessary to better understand PPARG regulation at chro-
matin level. Our data do not exclude an additional indirect
osteoblast diﬀerentiation-driven expression of PPARG because
PPARG-1 expression also increases in a DEX-independent dif-
ferentiating murine osteoblast cell model [9].
We demonstrate for the ﬁrst time in human osteoblasts the
presence and regulation of the two additional PPARG tran-
scripts 3 and 4. Moreover, we show that these transcripts as
well as PPARG-1 are homologously upregulated. Interest-
ingly, the magnitude of transcriptional regulation by both
ROSI and DEX is diﬀerent between PPARG-1, -3 and -4. This
points to a high order of complexity in promoter usage and
transcriptional control for these transcripts (Fig. 1). An even
higher order of control of levels of these PPARG transcripts
is demonstrated by the mRNA stability analyses. Both at tran-
scriptional control and stability, the PPARG-3 transcript is the
most sensitive. Overall these data are tempting to speculate
about a possible functional relevance. The combination of dif-
ferentially regulated PPARG transcript levels that encode for
the same protein with diﬀerential mRNA stabilities could en-
able a ﬁne-tuned protein expression level that may depend
on a speciﬁc cell type or metabolic state. However, this hypoth-
esis has to be functionally proven in future studies. Finally, the
diﬀerences in stabilities for the three PPARG transcripts-1, -3
and -4 are mechanistically intriguing and yet unexplained.
Transcript stability is usually dedicated to the 3 0-, but not
the 5 0-UTR in which these transcripts diﬀer. Thereby the cur-
rent data suggest also a role for this part of the transcript in
stability control.
In conclusion, the current study demonstrates that (1)
PPARG-1, -3 and -4 transcript levels encoding for PPARg-1
protein increase during diﬀerentiation of all four cell models
that were used in this study, (2) PPARG expression is directly
regulated by DEX and (3) PPARG regulates its expression it-
self by an auto-regulatory mechanism. We hypothesize from
this that cell-speciﬁc PPARG transcript-variant ratios, due to
their speciﬁc transcriptional regulation and stabilities, enable
a ﬁne-tuning of PPARG receptor-level regulation supportinga well-adjusted signal transduction between the cell and its
environment.
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